Treating psoriasis with biologic drugs that target the immune system can reduce early plaque buildup that clogs arteries, restricts blood flow, and leads to heart attacks and stroke. The association between psoriasis and occlusive cardiovascular events was noted originally nearly...
Secukinumab maintains improvements in psoriasis through 5 years of treatment
At the 2019 AAD meeting, 5-year follow-up data from the extension cohort of the phase 3 core trials ERASURE/FIXTURE was presented that showed that the IL-17A blocker secukinumab maintains long-term high levels of efficacy[1, 2]. Patients from the ERASURE/FIXTURE trials...